ReviewJournal of the National Cancer Center2025
Advancements in antibody-drug conjugates as cancer therapeutics.
Review in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Understanding the Potential of Antibody-Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review.Health science reports · 2026Article
- Article
- NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.Cancer cell international · 2026Article
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Investigation of Payloads and Related Impurities in the cysteine-linked Antibody-Drug Conjugate Using Mass Spectrometry Techniques.Applied biochemistry and biotechnology · 2026Article
- ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework.Pharmaceutics · 2026Review
- Recombinant Fusion Protein Composed of Hirudin and Annexin A5 Shows Anti-Coagulant Activity In Vitro.Applied biochemistry and biotechnology · 2026Article
- Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Antibody-Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives.Pharmaceutics · 2026Review
- An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies.Bioconjugate chemistry · 2026Article
- Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects.Frontiers in immunology · 2026Review
- Non-small cell lung cancer research: advances and persistent challenges.Frontiers in oncology · 2026Review
- Antibody conjugation of paclitaxel enables aqueous compatibility and enhances tumor-targeted efficacyFrontiers in pharmacology · 2026Article
- Selective real-time disulfide reduction with simultaneous fluorescent labeling of a humanized anti-cocaine mAb.Biochemistry and biophysics reports · 2025Article
- Strategic and Chemical Advances in Antibody-Drug Conjugates.Pharmaceutics · 2025Review
- Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) represent a promising approach in targeted cancer therapy, combining the targeted precision of antibodies with the potency of cytotoxic payloads to selectively target tumour cell whilst minimising off-target effects. This review provides a comprehensive analysis of ADCs, encompassing their structural components, mechanisms of action, and clinical applications. It also examines recent technological advancements, particularly in antibody engineering and linker design, aimed at enhancing therapeutic efficacy and safety. The current clinical landscape is outlined, highlighting approved ADCs and promising candidates in clinical trials, while also addressing key challenges such as stability, half-life, and systemic toxicity. This review is based on an extensive literature survey from major databases such as Scopus and Web of Science, with a focus on keywords like "antibody-drug conjugates", "ADC advancements", and "next-generation ADC technologies". By integrating insights from both preclinical and clinical perspectives, we highlight the transformative potential of ADCs in advancing modern cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.